# A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) 

Source: https://onco.cc/trials/nct03539744/  
OnCo record `nct03539744` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pomalidomide, Dexamethasone, Venetoclax in multiple myeloma, run by AbbVie, active and no longer recruiting.

## Summary

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma. is a phase 3 interventional study registered as NCT03539744 by AbbVie, with 265 participants enrolled, started 2018-10-22 and due to reach its primary completion in 2026-08. Interventions recorded: Pomalidomide, Dexamethasone, Venetoclax. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03539744
- Phase: 3
- Setting: A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma
- Sponsor: AbbVie
- Enrolled: 265

## Sources

- ClinicalTrials.gov NCT03539744: https://clinicaltrials.gov/study/NCT03539744

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Pomalidomide](https://onco.cc/drugs/pomalidomide/), [Venetoclax](https://onco.cc/drugs/venetoclax/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)

---
JSON: https://onco.cc/api/v1/entities/nct03539744.json